CLOs on the Move

Absci

www.absci.com

 
Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.absci.com
  • 18105 SouthEast Mill Plain Boulevard
    Vancouver, WA USA 98683
  • Phone: 360.949.1041

Executives

Name Title Contact Details
Sarah Korman
 General Counsel Profile

Similar Companies

Abpro

We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.

FIRSTMED HOLDING CORP

FIRSTMED HOLDING CORP is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Onconano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.

Jnana

Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients by targeting the cell`s metabolic gates.

jCyte

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.